Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION METHODOLOGY
  • 2.2.1 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
• 2.3 GROWTH RATE PROJECTIONS
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 HUMAN MICROBIOME MARKET OVERVIEW
• 4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE AND COUNTRY, 2024
• 4.3 HUMAN MICROBIOME MARKET, BY TYPE, 2025 VS. 2031
• 4.4 HUMAN MICROBIOME MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.5 HUMAN MICROBIOME MARKET, BY END USER, 2025

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Collaborative initiatives between organizations and academia
    • 5.2.1.2 Increasing number of startups/SMEs exploring microbiome
    • 5.2.1.3 Advancements in microbiome sequencing
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Complex regulatory policies
    • 5.2.2.2 High investments in commercializing microbiome drugs
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing demand for personalized medicines
    • 5.2.3.2 Emergence of postbiotics
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Slow patient adoption of microbiome-based therapies
    • 5.2.4.2 Complexities in developing microbiome therapies
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.3.1 DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY
    • 5.3.1.1 Market readiness
    • 5.3.1.2 Adoption
    • 5.3.1.3 Maturity
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.4.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022-2024
• 5.5 VALUE CHAIN ANALYSIS
  • 5.5.1 HUMAN MICROBIOME DRUGS
  • 5.5.2 HUMAN MICROBIOME SUPPLEMENTS
  • 5.5.3 HUMAN MICROBIOME DIAGNOSTICS
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 ECOSYSTEM SHIFT
    • 5.6.1.1 Specialized raw material and data suppliers
    • 5.6.1.2 Hot-bet innovator startups
    • 5.6.1.3 Integrated end users and prosumer models
    • 5.6.1.4 Regulatory and quality assurance orchestrators
    • 5.6.1.5 Diagnostics-driven personalization
    • 5.6.1.6 Microbiome-as-a-Service (Maas)
  • 5.6.2 EMERGING BUSINESS MODELS
    • 5.6.2.1 Emerging B2C model
    • 5.6.2.2 Personalized supplements model
  • 5.6.3 INTERCONNECTED MARKET DYNAMICS
• 5.7 INVESTMENT AND FUNDING SCENARIO
  • 5.7.1 MAJOR INVESTMENTS AND FUNDING BY KEY MARKET PLAYERS
  • 5.7.2 OTHER INVESTMENTS AND FUNDING
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 KEY TECHNOLOGIES
    • 5.8.1.1 Whole-genome sequencing
    • 5.8.1.2 16s RNA sequencing method
    • 5.8.1.3 Nanopore sequencing
  • 5.8.2 COMPLEMENTARY TECHNOLOGIES
    • 5.8.2.1 Metatranscriptomics
    • 5.8.2.2 Metagenomics
    • 5.8.2.3 Metabolomics
  • 5.8.3 ADJACENT TECHNOLOGIES
    • 5.8.3.1 Sample preparation
    • 5.8.3.2 Data analysis
    • 5.8.3.3 Library synthesis
• 5.9 PATENT ANALYSIS
• 5.10 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.11 CASE STUDY ANALYSIS
  • 5.11.1 EFFECT OF REBYOTA ON QUALITY OF LIFE IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
  • 5.11.2 ECOSPOR IV STUDY OF VOWST FOR CLOSTRIDIOIDES DIFFICILE INFECTION
  • 5.11.3 DELONG#3 STUDY FOR QUALITY OF LIFE IMPROVEMENT BY VSL#3 PROBIOTIC IN POST-COVID-19 PATIENTS
• 5.12 TARIFF AND REGULATORY ANALYSIS
  • 5.12.1 TARIFF DATA (HS CODE 3002.90)
  • 5.12.2 REGULATORY LANDSCAPE
    • 5.12.2.1 North America
      • 5.12.2.1.1 US
      • 5.12.2.1.2 Canada
    • 5.12.2.2 Europe
      • 5.12.2.2.1 UK
    • 5.12.2.3 Asia Pacific
      • 5.12.2.3.1 China
      • 5.12.2.3.2 Japan
      • 5.12.2.3.3 South Korea
      • 5.12.2.3.4 Australia
      • 5.12.2.3.5 Rest of Asia Pacific
  • 5.12.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 BARGAINING POWER OF SUPPLIERS
  • 5.13.2 BARGAINING POWER OF BUYERS
  • 5.13.3 THREAT OF NEW ENTRANTS
  • 5.13.4 THREAT OF SUBSTITUTES
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 PIPELINE ANALYSIS
• 5.16 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET
  • 5.16.1 INTRODUCTION
  • 5.16.2 MARKET POTENTIAL OF AI IN HUMAN MICROBIOME MARKET
  • 5.16.3 AI USE CASES
  • 5.16.4 KEY PLAYERS IMPLEMENTING AI
  • 5.16.5 FUTURE OF GENERATIVE AI IN HUMAN MICROBIOME MARKET
• 5.17 IMPACT OF US TARIFF ON HUMAN MICROBIOME MARKET
  • 5.17.1 KEY TARIFF RATES
  • 5.17.2 PRICE IMPACT ANALYSIS
  • 5.17.3 KEY IMPACT ON COUNTRY/REGION
    • 5.17.3.1 US
    • 5.17.3.2 Europe
    • 5.17.3.3 Asia Pacific
    • 5.17.3.4 Rest of the World
  • 5.17.4 IMPACT ON END-USE INDUSTRY
    • 5.17.4.1 Hospitals and clinics
    • 5.17.4.2 Long-term care facilities
• 5.18 MANAGING GLP-1 SIDE EFFECTS WITH MICROBIOME INTERVENTIONS
• 5.19 FUTURE TRENDS IN HUMAN MICROBIOME MARKET
  • 5.19.1 TYPE
  • 5.19.2 DISEASE
  • 5.19.3 END USER

6 HUMAN MICROBIOME MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 DRUGS
  • 6.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS IN LATE-STAGE CLINICAL TRIALS TO DRIVE MARKET
• 6.3 SUPPLEMENTS
  • 6.3.1 PROBIOTICS
    • 6.3.1.1 Increasing consumer awareness about probiotics for improved gut health and immunity to aid growth
  • 6.3.2 PREBIOTICS
    • 6.3.2.1 Rising development of targeted prebiotics to expedite growth
  • 6.3.3 SYNBIOTICS
    • 6.3.3.1 Growing demand for personalized treatment and rising incidence of dysbiosis to fuel market
• 6.4 DIAGNOSTICS
  • 6.4.1 INCREASING PRODUCT LAUNCHES AND TECHNOLOGY TRANSFER TO FACILITATE GROWTH

7 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)
  • 7.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT GROWTH
• 7.3 LIVE BACTERIA PRODUCTS (LBP)
  • 7.3.1 INCREASING CONSUMER FOCUS ON PREVENTIVE HEALTH TO AID GROWTH
• 7.4 OTHER MICROBIOME TYPES

8 HUMAN MICROBIOME MARKET, BY DISEASE

• 8.1 INTRODUCTION
• 8.2 INFECTIOUS DISEASES
  • 8.2.1 EMERGENCE OF MULTIDRUG-RESISTANT BACTERIA TO FOSTER GROWTH
• 8.3 GASTROINTESTINAL DISEASES
  • 8.3.1 INCREASING DEMAND FOR PERSONALIZED THERAPIES TO AID GROWTH
• 8.4 ENDOCRINE & METABOLIC DISORDERS
  • 8.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR METABOLIC DISORDERS TO BOOST MARKET
• 8.5 OTHER DISEASES

9 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION

• 9.1 INTRODUCTION
• 9.2 ORAL ROUTE OF ADMINISTRATION
  • 9.2.1 WIDESPREAD PATIENT ACCEPTANCE AND EXTENSIVE PRODUCT OFFERINGS TO ENCOURAGE GROWTH
• 9.3 RECTAL ROUTE OF ADMINISTRATION
  • 9.3.1 ABILITY TO RESTORE HEALTHY GUT TO FACILITATE GROWTH

10 HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE

• 10.1 INTRODUCTION
• 10.2 STRAIN DEVELOPMENT & OPTIMIZATION
  • 10.2.1 RISING DEMAND FOR TARGETED, STRAIN-SPECIFIC MICROBIOME THERAPIES TO BOOST MARKET
• 10.3 FERMENTATION & DOWNSTREAM PROCESSING
  • 10.3.1 GROWING DEMAND FOR CLINICAL-STAGE BIOTHERAPEUTICS TO DRIVE MARKET
• 10.4 FORMULATION & FILL/FINISH
  • 10.4.1 INCREASING STUDIES ON LIVE BIOTHERAPEUTIC PRODUCTS TO PROMOTE GROWTH
• 10.5 OTHER SERVICES

11 HUMAN MICROBIOME MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 HOSPITALS & CLINICS
  • 11.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT GROWTH
• 11.3 LONG-TERM CARE FACILITIES
  • 11.3.1 NEED FOR SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET
• 11.4 OTHER END USERS

12 HUMAN MICROBIOME MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 Favorable government initiatives and booming diagnostics sector to drive market
  • 12.2.3 CANADA
    • 12.2.3.1 Increasing prevalence of chronic diseases to expedite growth
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Rapid increase in government and private funding to propel market
  • 12.3.3 UK
    • 12.3.3.1 Significant government investments in microbiome research and presence of microbiome companies to propel growth
  • 12.3.4 FRANCE
    • 12.3.4.1 Growing focus on developing new products and services using microbiome data to boost market
  • 12.3.5 ITALY
    • 12.3.5.1 Rise in research activities to encourage growth
  • 12.3.6 SPAIN
    • 12.3.6.1 Favorable microbiome research landscape to support growth
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Rapidly expanding healthcare industry to accelerate growth
  • 12.4.3 JAPAN
    • 12.4.3.1 Booming geriatric population to contribute to growth
  • 12.4.4 INDIA
    • 12.4.4.1 Increasing number of human microbiome diagnostic companies to augment growth
  • 12.4.5 SOUTH KOREA
    • 12.4.5.1 Booming bio-health market to advance growth
  • 12.4.6 AUSTRALIA
    • 12.4.6.1 Growing number of product approvals to boost markt
  • 12.4.7 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Rising probiotics demand to drive market
  • 12.5.3 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST
  • 12.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Saudi Arabia
      • 12.6.2.1.1 Growing focus on healthcare infrastructure to fuel market
    • 12.6.2.2 UAE
      • 12.6.2.2.1 Increasing focus on immunotherapy and biotechnology to augment growth
    • 12.6.2.3 Rest of GCC countries
  • 12.6.3 REST OF MIDDLE EAST
• 12.7 AFRICA
  • 12.7.1 INCREASING STUDIES AND INITIATIVES ON MICROBIOME TO PROMOTE GROWTH
  • 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET
• 13.3 REVENUE ANALYSIS, 2022-2024
• 13.4 MARKET SHARE ANALYSIS, 2024
• 13.5 COMPANY VALUATION AND FINANCIAL METRICS
• 13.6 BRAND/PRODUCT COMPARISON
• 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 13.7.1 STARS
  • 13.7.2 EMERGING LEADERS
  • 13.7.3 PERVASIVE PLAYERS
  • 13.7.4 PARTICIPANTS
  • 13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 13.7.5.1 Company footprint
    • 13.7.5.2 Region footprint
    • 13.7.5.3 Product footprint
    • 13.7.5.4 Type footprint
    • 13.7.5.5 Disease footprint
• 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 13.8.1 PROGRESSIVE COMPANIES
  • 13.8.2 RESPONSIVE COMPANIES
  • 13.8.3 DYNAMIC COMPANIES
  • 13.8.4 STARTING BLOCKS
  • 13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 13.8.5.1 Detailed list of key startups/SMEs
    • 13.8.5.2 Competitive benchmarking of key emerging players/startups
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 INTERNATIONAL FLAVORS & FRAGRANCES INC.
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Deals
      • 14.1.1.3.2 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 SEED HEALTH, INC.
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches and approvals
      • 14.1.2.3.2 Deals
      • 14.1.2.3.3 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 SERES THERAPEUTICS
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches and approvals
      • 14.1.3.3.2 Deals
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 FERRING B.V.
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches and approvals
      • 14.1.4.3.2 Deals
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Key strengths
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 PENDULUM
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches and approvals
      • 14.1.5.3.2 Deals
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strengths
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 OPTIBIOTIX HEALTH PLC
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches and approvals
      • 14.1.6.3.2 Deals
  • 14.1.7 BIOGAIA
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Product launches and approvals
      • 14.1.7.3.2 Deals
      • 14.1.7.3.3 Expansions
  • 14.1.8 MAAT PHARMA
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Deals
      • 14.1.8.3.2 Other developments
  • 14.1.9 MICROBA
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Product launches and approvals
  • 14.1.10 BIOMEBANK
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Product launches and approvals
      • 14.1.10.3.2 Deals
      • 14.1.10.3.3 Expansions
  • 14.1.11 BIOHM HEALTH
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Deals
  • 14.1.12 ACTIAL FARMACEUTICA SRL
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
  • 14.1.13 RESBIOTIC
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Product launches and approvals
      • 14.1.13.3.2 Deals
      • 14.1.13.3.3 Expansions
  • 14.1.14 INFINANT HEALTH INC.
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Deals
  • 14.1.15 EXEGI PHARMA
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products offered
    • 14.1.15.3 Recent developments
      • 14.1.15.3.1 Deals
  • 14.1.16 FINCH THERAPEUTICS GROUP, INC.
    • 14.1.16.1 Business overview
    • 14.1.16.2 Products offered
    • 14.1.16.3 Recent developments
      • 14.1.16.3.1 Deals
  • 14.1.17 INFANT BACTERIAL THERAPEUTICS AB
    • 14.1.17.1 Business overview
    • 14.1.17.2 Products offered
  • 14.1.18 VIOME LIFESCIENCES
    • 14.1.18.1 Business overview
    • 14.1.18.2 Products offered
    • 14.1.18.3 Recent developments
      • 14.1.18.3.1 Product launches and approvals
  • 14.1.19 GENOVA DIAGNOSTICS
    • 14.1.19.1 Business overview
    • 14.1.19.2 Products offered
• 14.2 OTHER PLAYERS
  • 14.2.1 AOBIOME
  • 14.2.2 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.
  • 14.2.3 NUBIYOTA
  • 14.2.4 OXTHERA
  • 14.2.5 NEXBIOME
  • 14.2.6 VEDANTA BIOSCIENCES, INC.
  • 14.2.7 ENTEROME
  • 14.2.8 APSEN FARMACEUTICA
  • 14.2.9 METAGEN, INC.
  • 14.2.10 SNIPR BIOME
  • 14.2.11 MIKROBIOMIK
  • 14.2.12 SYNLOGIC
  • 14.2.13 GENETIC ANALYSIS
  • 14.2.14 METABIOMICS
  • 14.2.15 SUN GENOMICS, INC.

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS

List of Tables

• TABLE 1 HUMAN MICROBIOME MARKET: INCLUSIONS AND EXCLUSIONS
• TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
• TABLE 3 HUMAN MICROBIOME MARKET: RISK ANALYSIS
• TABLE 4 HUMAN MICROBIOME MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
• TABLE 5 INDUSTRY COLLABORATIONS IN HUMAN MICROBIOME MARKET, 2022-2024
• TABLE 6 LIST OF STARTUPS/SMES IN HUMAN MICROBIOME MARKET
• TABLE 7 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024 (USD)
• TABLE 8 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022-2024 (USD)
• TABLE 9 HUMAN MICROBIOME MARKET: MAJOR INVESTMENT AND FUNDING, 2022-2024
• TABLE 10 HUMAN MICROBIOME MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023-2024
• TABLE 11 HUMAN MICROBIOME MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
• TABLE 12 TARIFF DATA FOR HS CODE 3002.90
• TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 17 REGULATORY LANDSCAPE OF LIVE BIOTHERAPEUTIC PRODUCTS
• TABLE 18 HUMAN MICROBIOME MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
• TABLE 20 KEY BUYING CRITERIA, BY END USER
• TABLE 21 KEY PLAYERS IMPLEMENTING AI IN HUMAN MICROBIOME
• TABLE 22 COMPANIES LEVERAGING AI IN HUMAN MICROBIOME MARKET
• TABLE 23 US-ADJUSTED RECIPROCAL TARIFF RATES
• TABLE 24 KEY PRODUCT-RELATED TARIFF: PHARMACEUTICAL PRODUCTS, MISCELLANEOUS EDIBLE PREPARATIONS, AND PRODUCTS OF ANIMAL ORIGIN
• TABLE 25 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES
• TABLE 26 HUMAN MICROBIOME SUPPLEMENTS POSITIONED AS GLP-1 SUPPORT
• TABLE 27 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 28 HUMAN MICROBIOME DRUGS IN CLINICAL STAGE
• TABLE 29 HUMAN MICROBIOME DRUGS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 30 NORTH AMERICA: HUMAN MICROBIOME DRUGS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 31 ASIA PACIFIC: HUMAN MICROBIOME DRUGS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 32 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 33 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 34 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 35 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 37 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 38 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 39 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 40 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 41 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 42 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 43 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 44 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 45 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 46 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 47 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 48 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 49 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 50 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 51 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 52 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 53 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 54 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 55 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 56 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 58 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 59 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 60 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 61 HUMAN MICROBIOME DIAGNOSTICS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 62 NORTH AMERICA: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 63 EUROPE: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 64 ASIA PACIFIC: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 65 LATIN AMERICA: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 66 MIDDLE EAST: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 67 GCC COUNTRIES: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 68 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 69 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY REGION, 2023-2031 (USD MILLION)
• TABLE 70 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 71 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 72 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY REGION, 2023-2031 (USD MILLION)
• TABLE 73 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 74 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 75 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 76 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 77 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY REGION, 2023-2031 (USD MILLION)
• TABLE 78 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 79 HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 80 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 81 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 83 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 84 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 85 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 86 HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 87 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES
• TABLE 88 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 89 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 90 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 91 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 92 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 93 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 94 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 95 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 96 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 97 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 98 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 99 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 100 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 101 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 102 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 103 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 104 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 105 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 106 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 107 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 108 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 109 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 110 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 111 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 112 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 113 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2023-2031 (USD MILLION)
• TABLE 114 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 115 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 116 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 117 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 118 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2023-2031 (USD MILLION)
• TABLE 119 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 120 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY REGION, 2023-2031 (USD MILLION)
• TABLE 121 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 122 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 123 HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE, 2023-2031 (USD MILLION)
• TABLE 124 HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 125 HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 126 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 127 EUROPE: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 128 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 129 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 130 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 131 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 132 HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 133 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 134 EUROPE: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 135 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 136 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 137 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 138 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 139 HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 140 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 141 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 142 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 143 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 144 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 145 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 146 HUMAN MICROBIOME MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 147 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 148 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 149 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 150 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 151 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 152 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 153 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 154 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
• TABLE 155 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 156 US: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 157 US: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 158 US: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 159 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 160 US: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 161 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 162 CANADA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 163 CANADA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 164 CANADA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 165 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 166 CANADA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 167 EUROPE: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 168 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 169 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 170 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 171 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 172 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 173 EUROPE: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 174 EUROPE: KEY MACROECONOMIC INDICATORS
• TABLE 175 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 176 GERMANY: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 177 GERMANY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 178 GERMANY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 179 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 180 GERMANY: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 181 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 182 UK: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 183 UK: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 184 UK: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 185 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 186 UK: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 187 HUMAN MICROBIOME STARTUPS IN FRANCE
• TABLE 188 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 189 FRANCE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 190 FRANCE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 191 FRANCE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 192 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 193 FRANCE: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 194 ITALY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 195 ITALY: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 196 ITALY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 197 ITALY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 198 ITALY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 199 ITALY: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 200 SPAIN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 201 SPAIN: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 202 SPAIN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 203 SPAIN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 204 SPAIN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 205 SPAIN: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 206 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 207 REST OF EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 208 REST OF EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 209 REST OF EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 210 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 211 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 212 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 213 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 214 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 215 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 216 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 217 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 218 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 219 ASIA PACIFIC: MACROECONOMIC INDICATORS
• TABLE 220 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 221 CHINA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 222 CHINA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 223 CHINA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 224 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 225 CHINA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 226 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 227 JAPAN: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 228 JAPAN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 229 JAPAN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 230 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 231 JAPAN: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 232 HUMAN MICROBIOME DIAGNOSTICS COMPANIES IN INDIA
• TABLE 233 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 234 INDIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 235 INDIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 236 INDIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 237 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 238 INDIA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 239 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 240 SOUTH KOREA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 241 SOUTH KOREA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 242 SOUTH KOREA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 243 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 244 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 245 AUSTRALIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 246 AUSTRALIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 247 AUSTRALIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 248 AUSTRALIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 249 AUSTRALIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 250 AUSTRALIA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 251 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 252 REST OF ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 253 REST OF ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 254 REST OF ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 255 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 256 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 257 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 258 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 259 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 260 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 261 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 262 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 263 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 264 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
• TABLE 265 BRAZIL: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 266 BRAZIL: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 267 BRAZIL: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 268 BRAZIL: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 269 BRAZIL: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 270 BRAZIL: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 271 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 272 REST OF LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 273 REST OF LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 274 REST OF LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 275 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 276 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 277 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 278 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 279 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 280 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 281 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 282 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 283 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 284 MIDDLE EAST: KEY MACROECONOMIC INDICATORS
• TABLE 285 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 286 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 287 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 288 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 289 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 290 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 291 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 292 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 293 SAUDI ARABIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 294 SAUDI ARABIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 295 SAUDI ARABIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 296 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 297 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 298 UAE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 299 UAE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 300 UAE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 301 UAE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 302 UAE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 303 UAE: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 304 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 305 REST OF GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 306 REST OF GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 307 REST OF GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 308 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 309 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 310 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 311 REST OF MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 312 REST OF MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 313 REST OF MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 314 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 315 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 316 AFRICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 317 AFRICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 318 AFRICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 319 AFRICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
• TABLE 320 AFRICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
• TABLE 321 AFRICA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 322 AFRICA: KEY MACROECONOMIC INDICATORS
• TABLE 323 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET, JANUARY 2022-JULY 2025
• TABLE 324 HUMAN MICROBIOME MARKET: DEGREE OF COMPETITION, 2024
• TABLE 325 HUMAN MICROBIOME MARKET: REGION FOOTPRINT
• TABLE 326 HUMAN MICROBIOME MARKET: DRUG & SUPPLEMENT FOOTPRINT
• TABLE 327 HUMAN MICROBIOME MARKET: TYPE FOOTPRINT
• TABLE 328 HUMAN MICROBIOME MARKET: DISEASE FOOTPRINT
• TABLE 329 HUMAN MICROBIOME MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 330 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
• TABLE 331 HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
• TABLE 332 HUMAN MICROBIOME MARKET: DEALS, JANUARY 2022-JULY 2025
• TABLE 333 HUMAN MICROBIOME MARKET: EXPANSIONS, JANUARY 2022-JULY 2025
• TABLE 334 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW
• TABLE 335 INTERNATIONAL FLAVORS & FRAGRANCES INC.: PRODUCTS OFFERED
• TABLE 336 INTERNATIONAL FLAVORS & FRAGRANCES INC.: DEALS, JANUARY 2022-JULY 2025
• TABLE 337 INTERNATIONAL FLAVORS & FRAGRANCES INC.: EXPANSIONS, JANUARY 2022-JULY 2025
• TABLE 338 SEED HEALTH, INC.: COMPANY OVERVIEW
• TABLE 339 SEED HEALTH, INC.: PRODUCTS OFFERED
• TABLE 340 SEED HEALTH, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
• TABLE 341 SEED HEALTH, INC.: DEALS, JANUARY 2022-JULY 2025
• TABLE 342 SEED HEALTH, INC.: EXPANSIONS, JANUARY 2022-JULY 2025
• TABLE 343 SERES THERAPEUTICS: COMPANY OVERVIEW
• TABLE 344 SERES THERAPEUTICS: PRODUCTS OFFERED
• TABLE 345 SERES THERAPEUTICS: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
• TABLE 346 SERES THERAPEUTICS: DEALS, JANUARY 2022-JULY 2025
• TABLE 347 FERRING B.V.: COMPANY OVERVIEW
• TABLE 348 FERRING B.V.: PRODUCTS OFFERED
• TABLE 349 FERRING B.V.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
• TABLE 350 FERRING B.V.: DEALS, JANUARY 2022-JULY 2025
• TABLE 351 PENDULUM: COMPANY OVERVIEW
• TABLE 352 PENDULUM: PRODUCTS OFFERED
• TABLE 353 PENDULUM: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
• TABLE 354 PENDULUM: DEALS, JANUARY 2022-JULY 2025
• TABLE 355 OPTIBIOTIX HEALTH PLC: COMPANY OVERVIEW
• TABLE 356 OPTIBIOTIX HEALTH PLC: PRODUCTS OFFERED
• TABLE 357 OPTIBIOTIX HEALTH PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
• TABLE 358 OPTIBIOTIX HEALTH PLC: DEALS, JANUARY 2022-JULY 2025
• TABLE 359 BIOGAIA: COMPANY OVERVIEW
• TABLE 360 BIOGAIA: PRODUCTS OFFERED
• TABLE 361 BIOGAIA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
• TABLE 362 BIOGAIA: DEALS, JANUARY 2022-JULY 2025
• TABLE 363 BIOGAIA: EXPANSIONS, JANUARY 2022-JULY 2025
• TABLE 364 MAAT PHARMA: COMPANY OVERVIEW
• TABLE 365 MAAT PHARMA: PRODUCTS OFFERED
• TABLE 366 MAAT PHARMA: DEALS, JANUARY 2022-JULY 2025
• TABLE 367 MAAT PHARMA: OTHER DEVELOPMENTS, JANUARY 2022-JULY 2025
• TABLE 368 MICROBA: COMPANY OVERVIEW
• TABLE 369 MICROBA: PRODUCTS OFFERED
• TABLE 370 MICROBA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
• TABLE 371 BIOMEBANK: COMPANY OVERVIEW
• TABLE 372 BIOMEBANK: PRODUCTS OFFERED
• TABLE 373 BIOMEBANK: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
• TABLE 374 BIOMEBANK: DEALS, JANUARY 2022-JULY 2025
• TABLE 375 BIOMEBANK: EXPANSIONS, JANUARY 2022-JULY 2025
• TABLE 376 BIOHM HEALTH: COMPANY OVERVIEW
• TABLE 377 BIOHM HEALTH: PRODUCTS OFFERED
• TABLE 378 BIOHM HEALTH: DEALS, JANUARY 2022-JULY 2025
• TABLE 379 ACTIAL FARMACEUTICA SRL: COMPANY OVERVIEW
• TABLE 380 ACTIAL FARMACEUTICA SRL: PRODUCTS OFFERED
• TABLE 381 RESBIOTIC: COMPANY OVERVIEW
• TABLE 382 RESBIOTIC: PRODUCTS OFFERED
• TABLE 383 RESBIOTIC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
• TABLE 384 RESBIOTIC: DEALS, JANUARY 2022-JULY 2025
• TABLE 385 RESBIOTIC: EXPANSIONS, JANUARY 2022-JULY 2025
• TABLE 386 INFINANT HEALTH INC.: COMPANY OVERVIEW
• TABLE 387 INFINANT HEALTH INC.: PRODUCTS OFFERED
• TABLE 388 INFINANT HEALTH INC.: DEALS, JANUARY 2022-JULY 2025
• TABLE 389 EXEGI PHARMA: COMPANY OVERVIEW
• TABLE 390 EXEGI PHARMA: PRODUCTS OFFERED
• TABLE 391 EXEGI PHARMA: DEALS, JANUARY 2022-JULY 2025
• TABLE 392 FINCH THERAPEUTICS GROUP, INC.: COMPANY OVERVIEW
• TABLE 393 FINCH THERAPEUTICS GROUP, INC.: PRODUCTS OFFERED
• TABLE 394 FINCH THERAPEUTICS GROUP, INC.: DEALS, JANUARY 2022-JULY 2025
• TABLE 395 INFANT BACTERIAL THERAPEUTICS AB: COMPANY OVERVIEW
• TABLE 396 INFANT BACTERIAL THERAPEUTICS AB: PRODUCTS OFFERED
• TABLE 397 VIOME LIFESCIENCES: COMPANY OVERVIEW
• TABLE 398 VIOME LIFESCIENCES: PRODUCTS OFFERED
• TABLE 399 VIOME LIFESCIENCES: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
• TABLE 400 GENOVA DIAGNOSTICS: COMPANY OVERVIEW
• TABLE 401 GENOVA DIAGNOSTICS: PRODUCTS OFFERED
• TABLE 402 AOBIOME: COMPANY OVERVIEW
• TABLE 403 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
• TABLE 404 NUBIYOTA: COMPANY OVERVIEW
• TABLE 405 OXTHERA: COMPANY OVERVIEW
• TABLE 406 NEXBIOME: COMPANY OVERVIEW
• TABLE 407 VEDANTA BIOSCIENCES, INC.: COMPANY OVERVIEW
• TABLE 408 ENTEROME: COMPANY OVERVIEW
• TABLE 409 APSEN FARMACEUTICA: COMPANY OVERVIEW
• TABLE 410 METAGEN, INC.: COMPANY OVERVIEW
• TABLE 411 SNIPR BIOME: COMPANY OVERVIEW
• TABLE 412 MIKROBIOMIK: COMPANY OVERVIEW
• TABLE 413 SYNLOGIC: COMPANY OVERVIEW
• TABLE 414 GENETIC ANALYSIS: COMPANY OVERVIEW
• TABLE 415 METABIOMICS: COMPANY OVERVIEW
• TABLE 416 SUN GENOMICS, INC.: COMPANY OVERVIEW

List of Figures

• FIGURE 1 HUMAN MICROBIOME MARKET SEGMENTATION AND REGIONAL SCOPE
• FIGURE 2 RESEARCH DESIGN
• FIGURE 3 HUMAN MICROBIOME MARKET: BREAKDOWN OF PRIMARIES
• FIGURE 4 HUMAN MICROBIOME MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
• FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024
• FIGURE 6 ILLUSTRATIVE EXAMPLE OF INTERNATIONAL FLAVORS & FRAGRANCES INC.: REVENUE SHARE ANALYSIS, 2024
• FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
• FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
• FIGURE 9 HUMAN MICROBIOME MARKET: CAGR PROJECTIONS
• FIGURE 10 DATA TRIANGULATION METHODOLOGY
• FIGURE 11 HUMAN MICROBIOME MARKET, BY PRODUCT, 2025 VS. 2031 (USD MILLION)
• FIGURE 12 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2025 VS. 2031 (USD MILLION)
• FIGURE 13 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2024 VS. 2030 (USD MILLION)
• FIGURE 14 HUMAN MICROBIOME MARKET, BY DISEASE, 2025 VS. 2031 (USD MILLION)
• FIGURE 15 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2031 (USD MILLION)
• FIGURE 16 HUMAN MICROBIOME MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
• FIGURE 17 HUMAN MICROBIOME MARKET: GEOGRAPHICAL SNAPSHOT
• FIGURE 18 RISING DEMAND FOR PERSONALIZED MEDICINE AND ADVANCEMENTS IN MICROBIOME SEQUENCING TO DRIVE MARKET
• FIGURE 19 US AND LIVE BACTERIA PRODUCTS (LBP) SEGMENT LED NORTH AMERICAN MARKET IN 2024
• FIGURE 20 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
• FIGURE 21 US TO DOMINATE GLOBAL MARKET DURING FORECAST PERIOD
• FIGURE 22 HOSPITALS & CLINICS SEGMENT TO HOLD LARGEST MARKET SHARE IN 2025
• FIGURE 23 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 24 COMMERCIALIZATION ASPECTS OF MICROBIOMES FOR DRUGS VS. SUPPLEMENTS
• FIGURE 25 HUMAN MICROBIOME MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• FIGURE 26 DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY
• FIGURE 28 AVERAGE SELLING PRICE OF HUMAN MICROBIOME DRUGS, BY KEY PLAYER, 2024 (USD)
• FIGURE 29 AVERAGE SELLING PRICE OF HUMAN MICROBIOME DIAGNOSTICS, BY KEY PLAYER, 2024 (USD)
• FIGURE 30 AVERAGE SELLING PRICE TREND OF HUMAN MICROBIOME SUPPLEMENTS & DIAGNOSTICS, BY TYPE, 2022-2024 (USD)
• FIGURE 31 AVERAGE SELLING PRICE OF HUMAN MICROBIOME SUPPLEMENTS, BY REGION, 2024 (USD)
• FIGURE 32 VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME DRUGS
• FIGURE 33 VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME SUPPLEMENTS
• FIGURE 34 VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME DIAGNOSTICS
• FIGURE 35 HUMAN MICROBIOME MARKET: ECOSYSTEM ANALYSIS
• FIGURE 36 HUMAN MICROBIOME MARKET: INVESTMENT AND FUNDING SCENARIO, 2022-2024
• FIGURE 37 HUMAN MICROBIOME MARKET: PATENT ANALYSIS, JANUARY 2014-DECEMBER 2024
• FIGURE 38 REGULATORY LANDSCAPE OF LIVE BACTERIA PRODUCTS (LBP)
• FIGURE 39 HUMAN MICROBIOME MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 40 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
• FIGURE 41 KEY BUYING CRITERIA, BY END USER
• FIGURE 42 HUMAN MICROBIOME PIPELINE, BY DISEASE
• FIGURE 43 HUMAN MICROBIOME PIPELINE, BY PHASE
• FIGURE 44 HUMAN MICROBIOME PIPELINE, BY REGION
• FIGURE 45 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET
• FIGURE 46 AI USE CASES
• FIGURE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT
• FIGURE 48 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT
• FIGURE 49 REVENUE ANALYSIS OF KEY PLAYERS IN HUMAN MICROBIOME MARKET, 2022-2024 (USD MILLION)
• FIGURE 50 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HUMAN MICROBIOME MARKET, 2024
• FIGURE 51 EV/EBITDA OF KEY PLAYERS
• FIGURE 52 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
• FIGURE 53 HUMAN MICROBIOME MARKET: BRAND/PRODUCT COMPARISON
• FIGURE 54 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 55 HUMAN MICROBIOME MARKET: COMPANY FOOTPRINT
• FIGURE 56 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 57 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2024)
• FIGURE 58 SERES THERAPEUTICS: COMPANY SNAPSHOT (2023)
• FIGURE 59 FERRING B.V.: COMPANY SNAPSHOT (2024)
• FIGURE 60 OPTIBIOTIX HEALTH PLC: COMPANY SNAPSHOT (2024)
• FIGURE 61 BIOGAIA: COMPANY SNAPSHOT (2024)
• FIGURE 62 MAAT PHARMA: COMPANY SNAPSHOT (2024)
• FIGURE 63 MICROBA: COMPANY SNAPSHOT (2024)
• FIGURE 64 FINCH THERAPEUTICS GROUP, INC.: COMPANY SNAPSHOT (2023)